专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060046528A1 Electrical connector design and contact geometry and method of use thereof and methods of fabrication thereof 失效
标题翻译：电连接器设计和接触几何及其使用方法及其制造方法
公开(公告)号：US20060046528A1
公开(公告)日：2006-03-02
申请号：US10928473
申请日：2004-08-27
申请人： Brian Beaman , George Chiu , Keith Fogel , Paul Lauro , Daniel Morris , Da-Yuan Shih
发明人： Brian Beaman , George Chiu , Keith Fogel , Paul Lauro , Daniel Morris , Da-Yuan Shih
IPC分类号： H01R12/00
CPC分类号： H01R13/2464 , G01R1/06716 , G01R1/06727 , G01R1/07314 , G01R1/07357 , H01R12/714
摘要： A probe or an electrical connector comprises a substrate with a surface having a plurality of electrical contact locations. A shaped elongated electrical conductor has a first end coupled to one of the electrical contact locations and a second end thereof which projects away from the electrical contact location and through an aperture in a sheet of material. The sheet is disposed to be spaced apart from the surface of the substrate. At the second end of the elongated electrical conductor there is a tip structure, which is larger than the aperture in the sheet of material. The tip structure has a pointed portion thereof. The tip structure is disposed against contact locations of a contact surface. The electronic structure is moved towards the contact surface permitting the tip structure to penetrate into the surface of the electrical contact location thereon and to move, wipe, or vibrate across the surface thereof as the shaped elongated electrical conductor flexes as a result of being compressed by the movement of the electronic structure toward the contact surface.
摘要翻译：探针或电连接器包括具有多个电接触位置的表面的基底。成形细长的电导体具有联接到电接触位置之一的第一端和其第二端，其突出远离电接触位置并穿过材料片中的孔。片材被设置成与衬底的表面间隔开。在细长电导体的第二端，有一个尖端结构，其大于该材料片中的孔。尖端结构具有其尖端部分。尖端结构设置成抵靠接触表面的接触位置。电子结构朝向接触表面移动，允许尖端结构穿过其中的电接触位置的表面并且随着成形细长电导体由于被...的压缩而弯曲而在其表面上移动，擦拭或振动电子结构向接触表面移动。

2. 发明授权

US07470711B2 Piperidinyl substituted cyclohexane-1,4-diamines 有权
标题翻译：哌啶基取代的环己烷-1,4-二胺
公开(公告)号：US07470711B2
公开(公告)日：2008-12-30
申请号：US11376348
申请日：2006-03-15
申请人： George Chiu , Shengjian Li , Peter J. Connolly , Virginia L. Pulito , Jingchun Liu , Steven A. Middleton
发明人： George Chiu , Shengjian Li , Peter J. Connolly , Virginia L. Pulito , Jingchun Liu , Steven A. Middleton
IPC分类号： A61K31/451 , A61K31/453 , C07D211/22 , C07D405/12
CPC分类号： C07D211/14 , C07D211/22 , C07D405/12
摘要： The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.
摘要翻译：本发明涉及用于治疗良性前列腺肥大和下尿路症状的α1a/α1d肾上腺素受体调节剂的式（I）的哌啶取代的环己烷-1,4-二胺化合物及其药学上可接受的形式。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法和作为药物的新用途以及治疗方法。

3. 发明授权

US06608086B2 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06608086B2
公开(公告)日：2003-08-19
申请号：US09972801
申请日：2001-10-05
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： C07D40112
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.
摘要翻译：本发明提供了可用于治疗前列腺增生，抑制胆固醇合成和/或降低眼内压的二氢吡啶类。

4. 发明授权

US5780485A Use of .alpha..sub.1c specific compounds to treat benign prostatic hyperplasia 失效
标题翻译：使用α1c特异性化合物治疗良性前列腺增生
公开(公告)号：US5780485A
公开(公告)日：1998-07-14
申请号：US415681
申请日：1995-04-03
申请人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
发明人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
IPC分类号： A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/4427 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , A61K45/00 , A61P13/02 , A61P15/00 , A61P43/00 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
CPC分类号： C07D401/12 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D405/12 , C07D495/06 , C07C2102/08 , C07C2102/10 , C07C2102/12
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，其结合亲和力比结合亲和力高10倍，化合物与人α1B肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体结合，并且结合人α2肾上腺素能受体，其结合亲和力比结合亲和力低10倍该化合物与这种α1C肾上腺素能受体结合。提供符合这些标准的化合物。

5. 发明授权

US5403847A Use of .alpha..sub.1C specific compounds to treat benign prostatic hyperlasia 失效
标题翻译：使用α1C特异性化合物治疗良性前列腺增生
公开(公告)号：US5403847A
公开(公告)日：1995-04-04
申请号：US975867
申请日：1992-11-13
申请人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
发明人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
IPC分类号： A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/4427 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , A61K45/00 , A61P13/02 , A61P15/00 , A61P43/00 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
CPC分类号： C07D401/12 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/517 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07D211/58 , C07D405/12 , C07D495/06 , C07C2102/08 , C07C2102/10 , C07C2102/12
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，其结合亲和力比结合亲和力高10倍，化合物与人α1B肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体结合，并且结合人α2肾上腺素能受体，其结合亲和力比结合亲和力低10倍该化合物与这种α1C肾上腺素能受体结合。提供符合这些标准的化合物。

6. 发明授权

US07761687B2 Ultrascalable petaflop parallel supercomputer 失效
标题翻译：超平面petaflop平行超级计算机
公开(公告)号：US07761687B2
公开(公告)日：2010-07-20
申请号：US11768905
申请日：2007-06-26
申请人： Matthias A. Blumrich , Dong Chen , George Chiu , Thomas M. Cipolla , Paul W. Coteus , Alan G. Gara , Mark E. Giampapa , Shawn Hall , Rudolf A. Haring , Philip Heidelberger , Gerard V. Kopcsay , Martin Ohmacht , Valentina Salapura , Krishnan Sugavanam , Todd Takken
发明人： Matthias A. Blumrich , Dong Chen , George Chiu , Thomas M. Cipolla , Paul W. Coteus , Alan G. Gara , Mark E. Giampapa , Shawn Hall , Rudolf A. Haring , Philip Heidelberger , Gerard V. Kopcsay , Martin Ohmacht , Valentina Salapura , Krishnan Sugavanam , Todd Takken
IPC分类号： G06F15/173
CPC分类号： G06F15/17337
摘要： A massively parallel supercomputer of petaOPS-scale includes node architectures based upon System-On-a-Chip technology, where each processing node comprises a single Application Specific Integrated Circuit (ASIC) having up to four processing elements. The ASIC nodes are interconnected by multiple independent networks that optimally maximize the throughput of packet communications between nodes with minimal latency. The multiple networks may include three high-speed networks for parallel algorithm message passing including a Torus, collective network, and a Global Asynchronous network that provides global barrier and notification functions. These multiple independent networks may be collaboratively or independently utilized according to the needs or phases of an algorithm for optimizing algorithm processing performance. The use of a DMA engine is provided to facilitate message passing among the nodes without the expenditure of processing resources at the node.
摘要翻译： petaOPS规模的大规模并行超级计算机包括基于片上系统技术的节点架构，其中每个处理节点包括具有多达四个处理元件的单个专用集成电路（ASIC）。 ASIC节点通过多个独立网络互连，以最小的延迟最大化节点之间的数据包通信的吞吐量。多个网络可以包括用于并行算法消息传递的三个高速网络，包括Torus，集合网络和提供全局障碍和通知功能的全球异步网络。这些多个独立网络可以根据用于优化算法处理性能的算法的需求或阶段来协同或独立地利用。提供DMA引擎的使用以促进节点之间的消息传递，而不需要节点处理资源。

7. 发明授权

US07517885B2 Substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds 有权
标题翻译：取代的[4-（4-苯基 - 哌嗪-1-基） - 环己基] - 脲化合物
公开(公告)号：US07517885B2
公开(公告)日：2009-04-14
申请号：US11453128
申请日：2006-06-14
申请人： George Chiu , Peter J. Connolly , Jessica J. Liu , Steven A. Middleton , Virginia L. Pulito , Shengjian Li
发明人： George Chiu , Peter J. Connolly , Jessica J. Liu , Steven A. Middleton , Virginia L. Pulito , Shengjian Li
IPC分类号： A61K31/495 , C07D295/155
CPC分类号： C07D295/155 , C07D295/135
摘要： The present invention relates to substituted [4-(4-phenyl-piperazin-1-yl)-cyclohexyl]-urea compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
摘要翻译：本发明涉及用于治疗良性前列腺肥大的α1a/α1d肾上腺素受体调节剂的式（I）的取代的[4-（4-苯基 - 哌嗪-1-基） - 环己基] - 脲化合物及其药学上可接受的形式和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法和作为药物的新用途以及治疗方法。

8. 发明申请

US20070093500A1 Substituted isoindole-1,3-diones 有权
标题翻译：取代的异吲哚-1,3-二酮
公开(公告)号：US20070093500A1
公开(公告)日：2007-04-26
申请号：US11451196
申请日：2006-06-12
申请人： George Chiu , Peter Connolly , Jessica Liu , Steven Middleton , Virginia Pulito , Shengjian Li
发明人： George Chiu , Peter Connolly , Jessica Liu , Steven Middleton , Virginia Pulito , Shengjian Li
IPC分类号： A61K31/496 , C07D403/02 , C07D471/02
CPC分类号： C07D209/48 , C07D209/66 , C07D471/04
摘要： The present invention relates to substituted isoindole-1,3-dione compounds of Formula (I) and pharmaceutically acceptable forms thereof, as α1a/α1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as methods of treatment.
摘要翻译：本发明涉及式（I）的取代的异吲哚-1,3-二酮化合物及其药学上可接受的形式，作为用于治疗的α1a1/α1D1肾上腺素受体调节剂良性前列腺肥大和下尿路症状。本发明还涉及包含所述新化合物的药物组合物，制备这些新化合物的新方法和作为药物的新用途以及治疗方法。

9. 发明授权

US06602888B2 Use of &agr;1C specific compounds to treat benign prostatic hyperplasia 失效
标题翻译：使用α1C特异性化合物治疗良性前列腺增生
公开(公告)号：US06602888B2
公开(公告)日：2003-08-05
申请号：US09444783
申请日：1999-11-22
申请人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
发明人： Charles Gluchowski , Carlos C. Forray , George Chiu , Theresa A. Branchek , John M. Wetzel , Paul R. Hartig
IPC分类号： A61K31445
CPC分类号： A61K31/517 , A61K31/00 , A61K31/135 , A61K31/137 , A61K31/44 , A61K31/4409 , A61K31/445 , A61K31/4515 , A61K31/454 , A61K31/4545 , A61K31/505 , A61K31/55 , C07C211/30 , C07C215/50 , C07C215/52 , C07C217/58 , C07C217/60 , C07C2602/08 , C07C2602/10 , C07C2602/12 , C07D211/58 , C07D401/12 , C07D405/12 , C07D495/06
摘要： A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.
摘要翻译：一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的结合人α1C肾上腺素能受体的化合物，其结合亲和力大于化合物结合的结合亲和力的十倍涉及人α1A肾上腺素能受体，人α1B肾上腺素能受体和人组胺H1受体，并且以比结合亲和力大10倍的结合亲和力结合人α2肾上腺素能受体。到这种α1C肾上腺素能受体。提供符合这些标准的化合物。

10. 发明授权

US06211198B1 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06211198B1
公开(公告)日：2001-04-03
申请号：US09098699
申请日：1998-06-15
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： A61K314545
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n为1,2,3,4 或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C = C-（CH 2）k - ，其中h和k独立地相同或不同，为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H或直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物以及用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式